RxDoctor Payments Data

Naheed Shahid, MD

Internal Medicine · Dallas, TXNPI 1477508471

Payments from drug & device makers

$1,321in general payments, 2019–2025

Across 55 payments — averaging $24.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$197
  • Novo Nordisk$127
  • Galderma Laboratories, L.p.$125
  • Lilly USA, LLC$113
  • AbbVie$100
  • Abbott$98
  • plus $561 from 13 others

What the payments were for

  • Food & beverage$1,321100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,321 in reported general payments places this provider in the 70th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$19,776
Medicare patients
78
Services billed
271

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide17$32,677
MounjaroTirzepatide24$23,707
EliquisApixaban17$18,468
FarxigaDapagliflozin Propanediol21$16,178
Aimovig AutoinjectorErenumab-Aooe12$8,424
TrintellixVortioxetine Hydrobromide14$6,485
Esomeprazole Magnesium21$2,728
Ibandronate Sodium44$1,631
Levothyroxine Sodium126$1,592
Duloxetine Hcl36$1,471
SynthroidLevothyroxine Sodium22$1,319
Desvenlafaxine Succinate ErDesvenlafaxine Succinate39$1,275
Rosuvastatin Calcium90$1,241
Atorvastatin Calcium103$1,229
Pantoprazole Sodium66$1,217

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus$127$32,67717 claims
Lilly USA, LLCMounjaro$113$23,70724 claims
PfizerEliquis$67$18,46817 claims
AbbVieSynthroid, Armour Thyroid$100$1,74036 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →